Vimarsana
Biggest News Aggregation in the World

Page 10 - Nyse Path News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nyse Path. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nyse Path Today - Breaking & Trending Today

Invictus Private Wealth LLC Grows Stock Holdings in UiPath Inc. (NYSE:PATH) - Vimarsana News

Invictus Private Wealth LLC Grows Stock Holdings in UiPath Inc. (NYSE:PATH)

Invictus Private Wealth LLC boosted its holdings in UiPath Inc. (NYSE:PATH – Free Report) by 35.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 219,386 shares of the healthcare company’s stock after purchasing an additional 57,786 shares during the quarter. UiPath makes up 0.5% of Invictus Private Wealth LLC’s portfolio, making the stock […]

UiPath (NYSE:PATH) PT Raised to $17.00 - Vimarsana News

UiPath (NYSE:PATH) PT Raised to $17.00

UiPath (NYSE:PATH – Free Report) had its price objective upped by DA Davidson from $16.00 to $17.00 in a research report sent to investors on Thursday, Marketbeat.com reports. The brokerage currently has a neutral rating on the healthcare company’s stock. Several other equities analysts have also recently weighed in on PATH. Bank of America raised […]

Source: wkrb13.com
Royal Bank of Canada Raises UiPath (NYSE:PATH) Price Target to $19.00 - Vimarsana News

Royal Bank of Canada Raises UiPath (NYSE:PATH) Price Target to $19.00

UiPath (NYSE:PATH – Free Report) had its price target boosted by Royal Bank of Canada from $18.00 to $19.00 in a research report released on Thursday, MarketBeat reports. The firm currently has a sector perform rating on the healthcare company’s stock. Several other brokerages have also issued reports on PATH. Wells Fargo & Company lowered […]

Source: wkrb13.com
Needham & Company LLC Reaffirms Buy Rating for UiPath (NYSE:PATH) - Vimarsana News

Needham & Company LLC Reaffirms Buy Rating for UiPath (NYSE:PATH)

Needham & Company LLC reissued their buy rating on shares of UiPath (NYSE:PATH – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $20.00 price objective on the healthcare company’s stock. A number of other brokerages have also recently commented on PATH. Barclays boosted their price objective on UiPath […]

Bayesian Capital Management LP Sells 25,900 Shares of UiPath Inc. (NYSE:PATH) - Vimarsana News

Bayesian Capital Management LP Sells 25,900 Shares of UiPath Inc. (NYSE:PATH)

Bayesian Capital Management LP trimmed its position in shares of UiPath Inc. (NYSE:PATH – Free Report) by 12.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 176,800 shares of the healthcare company’s stock after selling 25,900 shares during […]

Source: wkrb13.com